drugset / Trial / NCT00747968

The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

NCT00747968

RandomizedCrossoverTriple-blindBasic science

Summary

30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.

Timeline

Start
2010-02
Primary completion
2010-11
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exenatide Peptide 0.066 unknown Other